摘要
Pancreatic ductal adenocarcinoma(PDAC)is a highly aggressive malignancy in which multimodality therapy is necessary to achieve good long-term outcomes.The recent seminar by Mizrahi et al.reported in The Lancet not only summarizes the fundamental knowledge of PDAC but also provides a concise overview of landmark studies that guide modern clinical practice(1).
